Clinical Trial Update: A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors [Phase 1]

View source ↗

Summary

Phase I trial update of T cells engineered to express an anti-GD2 chimeric antigen receptor in children and young adults with GD2-positive solid tumors, with co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Neuroblastoma
• Osteosarcoma
• Sarcoma

Drugs mentioned

• Anti-GD2 CAR T Cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Sarcoma, Osteosarcoma | Phase 1 | Status: COMPLETED